Tackling the cancer signal transduction “Labyrinth”: A combinatorial use of biochemical tools with mathematical models will enhance the identification of optimal targets for each molecular defect

No abstract is available for this paper.

• Publication year

  2014

• Venue

  Cancer

• Publication date

  2014-02-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1002/cncr.28424PMID 24186830
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Network Pharmacology Strategies Toward Multi-Target Anticancer Therapies: From Computational Models to Experimental Design Principles

  2014cited by this paper
• The molecular rationale of Src inhibition in colorectal carcinomas

  2014cited by this paper
• BRAF inhibitor (BRAFi) dabrafenib in combination with the MEK1/2 inhibitor (MEKi) trametinib in BRAFi-naive and BRAFi-resistant patients (pts) with BRAF mutation-positive metastatic melanoma (MM).

  2013cited by this paper
• Molecular screening for cancer treatment optimization: MOSCATO 01 - A prospective molecular triage trial, interim results

  2013cited by this paper
• Genomic medicine frontier in human solid tumors: prospects and challenges.

  2013cited by this paper
• Amplification of the MET receptor to drive resistance to anti-EGFR therapies in colorectal cancer.

  2013cited by this paper
• Cell signalling analyses in the functional genomics era.

  2013cited by this paper
• Existing and emerging technologies for tumor genomic profiling.

  2013cited by this paper
• Randomized proteomic stratified phase III study of second-line erlotinib (E) versus chemotherapy (CT) in patients with inoperable non-small cell lung cancer (PROSE).

  2013cited by this paper
• Genome-wide epigenetic regulation of miRNAs in cancer.

  2013cited by this paper
• Analysis of KRAS/NRAS and BRAF mutations in the phase III PRIME study of panitumumab (pmab) plus FOLFOX versus FOLFOX as first-line treatment (tx) for metastatic colorectal cancer (mCRC).

  2013cited by this paper
• Biomarkers (BM) France: Results of routine EGFR, HER2, KRAS, BRAF, PI3KCA mutations detection and EML4-ALK gene fusion assessment on the first 10,000 non-small cell lung cancer (NSCLC) patients (pts).

  2013cited by this paper
• ELECANS - an integrated model development environment for multiscale cancer systems biology

  2013cited by this paper
• Role of HER3 expression and PTEN loss in patients with HER2-overexpressing metastatic breast cancer (MBC) who received taxane plus trastuzumab treatment

  2013cited by this paper
• Chemical kinetic mechanistic models to investigate cancer biology and impact cancer medicine

  2013cited by this paper
• Next-generation sequencing reveals high concordance of recurrent somatic alterations between primary tumor and metastases from patients with non-small-cell lung cancer.

  2013cited by this paper
• A phase I study of MM-121 in combination with multiple anticancer therapies in patients with advanced solid tumors.

  2013cited by this paper
• Princess Margaret Cancer Centre (PMCC) Integrated Molecular Profiling in Advanced Cancers Trial (IMPACT) using genotyping and targeted next-generation sequencing (NGS).

  2013cited by this paper
• Survival differences in patients (pts) with resected rectal cancer who received neoadjuvant therapy with or without postoperative chemotherapy (CT).

  2013cited by this paper
• Coexpression of HER3 as a predictor of survival in HER2-positve breast cancer patients.

  2013cited by this paper
• Cancer statistics, 2013

  2013cited by this paper
• Predicting the future: towards symbiotic computational and experimental angiogenesis research.

  2013cited by this paper
• Construction of cell type-specific logic models of signaling networks using CellNOpt.

  2013cited by this paper
• A community-based program for personalized cancer care using next-generation sequencing (NGS).

  2013cited by this paper
• Building a personalized medicine infrastructure at a major cancer center.

  2013cited by this paper
• Targeting low-expressing ERBB-2 and acquired resistant high-expressing ERBB-2 breast carcinomas.

  2013cited by this paper
• Clinical analysis and interpretation of cancer genome data.

  2013cited by this paper
• Integrated genomic analysis by whole exome and transcriptome sequencing of tumor samples from EGFR-mutant non-small-cell lung cancer (NSCLC) patients (p) with acquired resistance to erlotinib.

  2013cited by this paper
• Systematic Identification of Signal-Activated Stochastic Gene Regulation

  2013cited by this paper
• Cancer stem cells: an evolving concept

  2012cited by this paper
• Computational Medicine: Translating Models to Clinical Care

  2012cited by this paper
• Multiscale Models of Cell Signaling

  2012cited by this paper
• Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer

  2012cited by this paper
• Computational modeling and multilevel cancer control interventions.

  2012cited by this paper
• Determining Duration of HER2-Targeted Therapy Using Stem Cell Extinction Models

  2012cited by this paper
• Computational model of EGFR and IGF1R pathways in lung cancer: a Systems Biology approach for Translational Oncology.

  2012cited by this paper
• Computational modeling of single-cell migration: the leading role of extracellular matrix fibers.

  2012cited by this paper
• The Mechanics of Metastasis: Insights from a Computational Model

  2012cited by this paper
• Multi-scale agent-based brain cancer modeling and prediction of TKI treatment response: Incorporating EGFR signaling pathway and angiogenesis

  2012cited by this paper
• Modelling the correlation between EGFr expression and tumour cell radiosensitivity, and combined treatments of radiation and monoclonal antibody EGFr inhibitors

  2012cited by this paper
• Genome and transcriptome sequencing of lung cancers reveal diverse mutational and splicing events

  2012cited by this paper
• Transcription Factor Networks as Targets for Therapeutic Intervention of Cancer: The Breast Cancer Paradigm

  2011cited by this paper
• Computational Modeling of Allosteric Communication Reveals Organizing Principles of Mutation-Induced Signaling in ABL and EGFR Kinases

  2011cited by this paper
• Screening for Compounds That Modulate Epigenetic Regulation of the Transcriptome

  2011cited by this paper
• Computational oncology.

  2011cited by this paper
• The proteomics of cancer stem cells. Potential clinical applications for innovative research in oncology

  2011cited by this paper
• Dissecting cancer through mathematics: from the cell to the animal model

  2010cited by this paper
• Kinase-Dead BRAF and Oncogenic RAS Cooperate to Drive Tumor Progression through CRAF

  2010cited by this paper
• RAF inhibitors transactivate RAF dimers and ERK signaling in cells with wild-type BRAF

  2010cited by this paper
• An ErbB3 antibody, MM-121, is active in cancers with ligand-dependent activation.

  2010cited by this paper
• RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth

  2010cited by this paper
• Targeting MET as a strategy to overcome crosstalk-related resistance to EGFR inhibitors.

  2009cited by this paper
• Caspase-8 for Outer Harmony

  2009cited by this paper
• Therapeutically Targeting ErbB3: A Key Node in Ligand-Induced Activation of the ErbB Receptor–PI3K Axis

  2009cited by this paper
• Chemical Biology Approaches to Probe the Proteome

  2008cited by this paper
• Therapies directed against epidermal growth factor receptor in aerodigestive carcinomas.

  2007cited by this paper
• Post-translational modifications and regulation of the RAS superfamily of GTPases as anticancer targets

  2007cited by this paper
• Trastuzumab--mechanism of action and use in clinical practice.

  2007cited by this paper
• Ligand-dependent responses of the ErbB signaling network: experimental and modeling analyses

  2007cited by this paper
• Trastuzumab--mechanism of action and use.

  2007cited by this paper
• Molecular Systems Biology 7; Article number 501; doi:10.1038/msb.2011.35 Citation: Molecular Systems Biology 7:501

  year unknowncited by this paper

• Corrected score methods for estimating Bayesian networks with error‐prone nodes

  2020influential citation
• Addressing the elephant in the room, therapeutic resistance in non-small cell lung cancer, with epigenetic therapies

  2016cites this paper
• Targeting Androgen/Estrogen Receptors Crosstalk in Cancer.

  2016cites this paper
• The potential for chemical mixtures from the environment to enable the cancer hallmark of sustained proliferative signalling.

  2015cites this paper
• Conditional robustness analysis for fragility discovery and target identification in biochemical networks and in cancer systems biology

  2015cites this paper
• Wilhelm Engström1,*, Philippa Darbre2, Staffan Eriksson3, Linda Gulliver4,†, Tove Hultman1,2, Michalis V.Karamouzis5, James E.Klaunig6, Rekha Mehta7, Kim Moorwood8, Thomas Sanderson9, Hideko Sone10, Pankaj Vadgama11, Gerard Wagemaker12, Andrew Ward8, Neetu Singh13,‡, Fahd Al-Mulla14,‡, Rabeah Al-Te

  2015cites this paper
• Toward Genomic Based Personalized Mathematical Models for Breast Cancer Tumor Growth

  2014cites this paper